Product logins

Find logins to all Clarivate products below.


ANALYST CALL: Coming to America: Sandoz Files the First Biosimilar in the United States

Outline

• Sandoz’s biosimilar filgrastim development program

• Zarzio’s European performance

• U.S. oncologists’ expected uptake of biosimilar filgrastim

• U.S. payers’ price expectations and strategy to drive uptake

• Competitive landscape for biosimilars in the United States

• Potential differentiation strategies

• Next milestones for the U.S. biosimilar market

• Q&A

Related Market Assessment Reports

Report
Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
Report
Biosimilars – Current Treatment – Immunology
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Forecast Methodology and General Market Assumptions
In 2023, sales of branded biologics for oncology, immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $150 billion in the major pharmaceutical…
Report
Biosimilars – Forecast – Neurology
In 2023, sales of branded MAb biologics in neurology exceeded $10 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, the…